Indication | Ontology | MeSH | ICD-10 |
---|---|---|---|
multiple myeloma | — | D009101 | C90.0 |
Expiration | Code | ||
---|---|---|---|
teclistamab, Tecvayli, Janssen Biotech, Inc. | |||
2029-10-25 | Orphan excl. |
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
---|---|---|---|---|---|---|---|---|---|
Multiple myeloma | D009101 | — | C90.0 | 4 | 7 | 4 | 1 | 5 | 20 |
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
---|---|---|---|---|---|---|---|---|---|
Hematologic neoplasms | D019337 | — | — | 2 | 2 | — | — | — | 3 |
Smoldering multiple myeloma | D000075122 | — | — | — | 1 | — | — | — | 1 |
Drug common name | Teclistamab |
INN | teclistamab |
Description | Teclistamab, sold under the brand name Tecvayli, is a human bispecific monoclonal antibody used for the treatment of relapsed and refractory multiple myeloma. It is a bispecific antibody that targets the CD3 receptor expressed on the surface of T-cells and B-cell maturation antigen (BCMA), which is expressed on the surface of malignant multiple myeloma B-lineage cells.
|
Classification | Antibody |
Drug class | monoclonal antibodies |
Image (chem structure or protein) | |
Structure (InChI/SMILES or Protein Sequence) | — |
PDB | — |
CAS-ID | 2119595-80-9 |
RxCUI | — |
ChEMBL ID | CHEMBL4594505 |
ChEBI ID | — |
PubChem CID | — |
DrugBank | DB16655 |
UNII ID | 54534MX6Z9 (ChemIDplus, GSRS) |